- Home
- XFOR vs GNTA Comparison
XFOR vs GNTA Comparison
Compare XFOR & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- GNTA
- Stock Information
- Founded
- XFOR 2014
- GNTA 2014
- Country
- XFOR United States
- GNTA Italy
- Employees
- XFOR N/A
- GNTA N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XFOR Health Care
- GNTA Health Care
- Exchange
- XFOR Nasdaq
- GNTA Nasdaq
- Market Cap
- XFOR 118.4M
- GNTA 96.9M
- IPO Year
- XFOR N/A
- GNTA 2021
- Fundamental
- Price
- XFOR $0.40
- GNTA $5.06
- Analyst Decision
- XFOR Strong Buy
- GNTA Strong Buy
- Analyst Count
- XFOR 4
- GNTA 1
- Target Price
- XFOR $2.88
- GNTA $25.00
- AVG Volume (30 Days)
- XFOR 4.9M
- GNTA 8.6K
- Earning Date
- XFOR 11-13-2024
- GNTA 01-01-0001
- Dividend Yield
- XFOR N/A
- GNTA N/A
- EPS Growth
- XFOR N/A
- GNTA N/A
- EPS
- XFOR N/A
- GNTA N/A
- Revenue
- XFOR $1,123,000.00
- GNTA N/A
- Revenue This Year
- XFOR N/A
- GNTA N/A
- Revenue Next Year
- XFOR $596.79
- GNTA N/A
- P/E Ratio
- XFOR N/A
- GNTA N/A
- Revenue Growth
- XFOR N/A
- GNTA N/A
- 52 Week Low
- XFOR $0.26
- GNTA $2.20
- 52 Week High
- XFOR $1.60
- GNTA $7.28
- Technical
- Relative Strength Index (RSI)
- XFOR 39.99
- GNTA 50.84
- Support Level
- XFOR $0.26
- GNTA $4.61
- Resistance Level
- XFOR $0.68
- GNTA $5.44
- Average True Range (ATR)
- XFOR 0.08
- GNTA 0.46
- MACD
- XFOR -0.01
- GNTA -0.05
- Stochastic Oscillator
- XFOR 34.01
- GNTA 56.54
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.